Literature DB >> 14726521

Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells.

Haojie Huang1, David C Muddiman, Donald J Tindall.   

Abstract

The ability of androgens to inhibit apoptosis in both normal and malignant prostatic cells has been well documented. However, the underlying mechanisms are understood poorly. Here we demonstrated that forkhead transcription factor FKHR (FOXO1)-induced death of LNCaP cells was blocked by a synthetic androgen R1881. Androgen treatment also resulted in a reduction in transcriptional activity of FKHR in these cells. Moreover, treatment of LNCaP cells with R1881 led to a decrease in the intact FKHR protein (70 kDa) and an increase in a faster migrating protein band (60 kDa). Androgen-enhanced appearance of the 60-kDa protein was diminished specifically by lysosomal acidic cysteine protease inhibitors. Mass spectrometry analyses of the purified FLAG-tagged 70- and 60-kDa proteins demonstrated that the 60-kDa species is a FKHR protein product that lacks about 120 amino acid residues of the C-terminal end. Mutagenesis of the basic amino acid Arg(537) in the protease cleavage region, as suggested by mass spectrometry, abrogated both the androgen-induced accumulation of the 60-kDa product and decrease in cell death induced by FKHR, suggesting that the residue Arg(537) is a potential protease cleavage site. Finally, ectopic expression of the first 537 amino acids of FKHR produced an inhibitory effect on transcriptional activity of the intact protein. Together, these results suggest that androgens induce increased activity of an acidic cysteine protease, which in turn cleaves FKHR. This provides a mechanism by which androgens protect prostate cancer cells from the killing effect of FKHR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14726521     DOI: 10.1074/jbc.M314143200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation.

Authors:  Lars P Van Der Heide; Marco F M Hoekman; Marten P Smidt
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

2.  Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.

Authors:  Huarui Lu; Ping Liu; Yunqian Pan; Haojie Huang
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

3.  Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

Authors:  Yanyuan Wu; Yayha Elshimali; Marianna Sarkissyan; Hezla Mohamed; Sheila Clayton; Jaydutt V Vadgama
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

4.  The function of FOXO1 in the late phases of the cell cycle is suppressed by PLK1-mediated phosphorylation.

Authors:  Chengfu Yuan; Lei Wang; Liang Zhou; Zheng Fu
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

5.  Prostate Cancer Chemoprevention Targeting High Risk Populations: Model for Trial Design and Outcome Measures.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Julio Pow-Sang; Philippe E Spiess; Shanjayla Connors; Ganna Chornukur; Shohreh Iravani Dickinson; Wenlong Bai; Christopher R Williams; Raoul Salup; Wui Fu
Journal:  J Cancer Sci Ther       Date:  2012-01-10

6.  Activation of FOXO1 is critical for the anticancer effect of methylseleninic acid in prostate cancer cells.

Authors:  Haitao Zhang; Jian Fang; Dian Yao; Yue Wu; Clement Ip; Yan Dong
Journal:  Prostate       Date:  2010-09-01       Impact factor: 4.104

7.  USP6 Confers Sensitivity to IFN-Mediated Apoptosis through Modulation of TRAIL Signaling in Ewing Sarcoma.

Authors:  Ian C Henrich; Robert Young; Laura Quick; Andre M Oliveira; Margaret M Chou
Journal:  Mol Cancer Res       Date:  2018-08-21       Impact factor: 5.852

8.  Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP.

Authors:  Oskar W Rokhlin; Agshin F Taghiyev; Natalya V Guseva; Rebecca A Glover; Peter M Chumakov; Julia E Kravchenko; Michael B Cohen
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

9.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

10.  Inhibition of the progesterone nuclear receptor during the bone linear growth phase increases peak bone mass in female mice.

Authors:  Wei Yao; Weiwei Dai; Mohammad Shahnazari; Aaron Pham; Zhiqiang Chen; Haiyan Chen; Min Guan; Nancy E Lane
Journal:  PLoS One       Date:  2010-07-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.